Laboratory Corporation of America Holdings has announced the availability of Thermo Scientific ImmunoCAP allergy testing products from Thermo Fisher Scientific, Inc. LabCorp provides innovative testing technologies that facilitate earlier and more accurate diagnosis, treatment, and monitoring of diseases and medical conditions. The agreement provides LabCorp with access to Thermo Fisher's ImmunoCAP allergy testing portfolio of more than 600 allergens and 100 allergen components.
“LabCorp offers an extensive test menu which supports a diagnosis of allergy and, just as importantly, can assist in ruling out allergies as a source of symptoms and thereby suggest other etiologies,” says Dr. Mark Brecher, LabCorp's Chief Medical Officer. “We will continue to offer a comprehensive range of tests for regional allergies, food allergies, oral allergy syndrome, pediatric allergens, and workplace allergy exposures, and we will develop customized panels to improve treatment practices and enhance patient outcomes.”
